Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK-gamma), also known as NF-kappa-B essential modulator (NEMO), is the non-catalytic regulatory subunit of the IκB kinase (IKK) complex [UniProt: P51948]. It plays a pivotal role in the canonical NF-κB signaling pathway by acting as a scaffold that assembles the catalytic subunits, IKK-alpha and IKK-beta, and linking them to upstream activators such as TNF receptors, Toll-like receptors, and T-cell receptors [PubMed: 11048709]. Upon stimulation, IKK-gamma undergoes polyubiquitination, which facilitates the activation of the catalytic subunits; these then phosphorylate IκB proteins, marking them for proteasomal degradation and allowing NF-κB transcription factors to enter the nucleus [PubMed: 24037306]. Mutations in the IKBKG gene encoding this protein are responsible for several X-linked genetic disorders, including incontinentia pigmenti and anhidrotic ectodermal dysplasia with immunodeficiency [NCBI: NBK1116]. In drug discovery, IKK-gamma is targeted to treat chronic inflammatory diseases and certain cancers where NF-κB is constitutively active. Therapeutic approaches often utilize NEMO-binding domain (NBD) peptides to disrupt the interaction between IKK-gamma and the catalytic subunits, thereby preventing complex formation and signaling [PubMed: 11048709]. However, because NF-κB is essential for normal immune function and cell survival, systemic inhibition of IKK-gamma carries significant risks of immunosuppression and toxicity [PubMed: 15034166].
Disruption of the IKK complex assembly by preventing the interaction between the NEMO regulatory subunit and the catalytic IKK subunits [PubMed: 11048709].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK-gamma) (NEMO).